Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity

Active, not recruitingOBSERVATIONAL
Enrollment

23

Participants

Timeline

Start Date

August 27, 2021

Primary Completion Date

August 27, 2026

Study Completion Date

August 27, 2026

Conditions
Breast CancerHER2-positive Breast CancerHER2-positive Metastatic Breast CancerBreast Cancer Stage IBreast Cancer Stage IIBreast Cancer Stage IIIBreast Cancer Stage IVCardiotoxicity
Interventions
DIAGNOSTIC_TEST

Cardiopulmonary Exercise Test

All enrolled participants will undergo a cardiopulmonary exercise test (CPET). The CPET will be conducted using an electronic motorized treadmill with 12-lead ECG monitoring performed by ACSM-certified exercise physiologists.

DIAGNOSTIC_TEST

Echocardiogram

Resting assessment of LVEF and GLS will be evaluated through Conventional 2D and Doppler echocardiograms will be performed per protocol using a commercially available ultrasound scanner, according to the American Society of Echocardiography (ASE) recommendations for a comprehensive examination.

DIAGNOSTIC_TEST

Echocardiography

As soon as possible following completion of the CPET, subjects will be placed in the supine position and 2D echocardiographic images will be obtained in the apical 4-/ 3-/2-chamber views.

Trial Locations (1)

10021

Memorial Sloan - Kettering Cancer Center, New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER